We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.50 | -0.35% | 422.00 | 420.50 | 423.50 | 422.00 | 420.00 | 421.00 | 2,230 | 09:13:01 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 89.54M | -184.16M | -1.7479 | -2.42 | 446.2M |
From Dec 2022 to Dec 2024
TIDMOXB
RNS Number : 8078E
Oxford Biomedica PLC
03 July 2023
PDMR Dealings
Oxford, UK - 3 July 2023: Oxford Biomedica plc ("Oxford Biomedica" or " the Company") (LSE:OXB), a quality and innovation-led viral vector CDMO, today announces that Non-Executive Directors Dr. Michael Hayden, Dr Heather Preston and Catherine Moukheibir have purchased ordinary shares in the Company pursuant to a trading plan put in place on 7 October 2022.
By way of background, and as stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to GBP50,000 per annum may be paid to any Non-Executive Director recruited from or based outside of the UK to reflect market levels of remuneration for Non-Executive Directors not based in the UK, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition. The ordinary shares were all purchased at 430p and the number of ordinary shares purchased along with further information is set out in the table below:
Hot Features
Premium
Name of PDMR Number of Number of ordinary T otal number of
o rdinary shares now held ordinary shares
shares purchased held as a percentage
of the Company's
share capital
Dr. M ichael Hayden 6,684 17,973 0.019
------------------ ------------------- ----------------------
Dr. Heather Preston 6,684 18,298 0.019
------------------ ------------------- ----------------------
C athrine Moukheibir 6,684 18,530 0.019
------------------ ------------------- ----------------------
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Dr. Michael Hayden
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP4.30 6,684
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 6,684
GBP28,741.20
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2023-07-03
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Dr. Heather Preston
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP4.30 6,684
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 6,684
GBP28,741.20
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2023-07-03
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Catherine Moukheibir
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP4.30 6,684
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 6,684
GBP28,741.20
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2023-07-03
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
-Ends-
For further information, please contact: Oxford Biomedica plc: Tel: +44 (0)1865 783 000 Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com , www.oxbsolutions.com , and follow us on LinkedIn , Twitter and YouTube .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFFEDEIVIIV
(END) Dow Jones Newswires
July 03, 2023 11:31 ET (15:31 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
